Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2016 | Nov. 01, 2016 | |
Document and Entity Information | ||
Entity Registrant Name | Cerecor Inc. | |
Entity Central Index Key | 1,534,120 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 9,264,141 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q3 |
Balance Sheets
Balance Sheets - USD ($) | Sep. 30, 2016 | Dec. 31, 2015 |
Current assets: | ||
Cash and cash equivalents | $ 8,815,177 | $ 21,161,967 |
Grants receivable | 379,256 | |
Prepaid expenses and other current assets | 210,023 | 401,550 |
Restricted cash, current portion | 87,882 | 58,832 |
Total current assets | 9,492,338 | 21,622,349 |
Property and equipment, net | 40,393 | 35,216 |
Restricted cash, net of current portion | 50,001 | |
Total assets | 9,582,732 | 21,657,565 |
Current liabilities: | ||
Current portion of long term debt, net of discount | 3,189,793 | 3,208,074 |
Accounts payable | 809,151 | 678,109 |
Accrued expenses and other current liabilities | 3,361,189 | 1,885,458 |
Warrant liability | 44,992 | 27,606 |
Unit purchase option liability | 90,780 | 50,571 |
Total current liabilities | 7,495,905 | 5,849,818 |
Long term debt, net of current portion and discount | 2,353,482 | |
Other long term liabilities | 1,500,000 | 370,538 |
Total liabilities | 8,995,905 | 8,573,838 |
Stockholders? equity: | ||
Preferred stock?$0.001 par value; 5,000,000 shares authorized at September 30, 2016 and December 31, 2015; zero shares issued and outstanding at September 30, 2016 and December 31, 2015 | ||
Common stock?$0.001 par value; 200,000,000 shares authorized at September 30, 2016 and December 31, 2015; 9,075,143 and 8,650,143 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively | 9,075 | 8,650 |
Additional paid-in capital | 68,974,131 | 66,638,557 |
Accumulated deficit | (68,396,379) | (53,563,480) |
Total stockholders' equity | 586,827 | 13,083,727 |
Total liabilities and stockholders' equity | $ 9,582,732 | $ 21,657,565 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2016 | Dec. 31, 2015 |
Balance Sheets | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Common stock, Par value | $ 0.001 | $ 0.001 |
Common stock, Shares authorized | 200,000,000 | 200,000,000 |
Common stock, Shares issued | 9,075,143 | 8,650,143 |
Common stock, Shares outstanding | 9,075,143 | 8,650,143 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | |
Statements of Operations | ||||
Grant revenue | $ 321,497 | $ 971,985 | ||
Operating expenses: | ||||
Research and development | 4,581,605 | $ 1,237,375 | 9,376,633 | $ 4,835,981 |
General and administrative | 1,703,188 | 721,658 | 5,989,053 | 2,498,475 |
Loss from operations | (5,963,296) | (1,959,033) | (14,393,701) | (7,334,456) |
Other income (expense) | ||||
Change in fair value of warrant liability, unit purchase option liability and investor rights obligation | (101,246) | 1,465,422 | (57,595) | 1,127,683 |
Interest expense, net | (104,183) | (197,470) | (381,603) | (634,772) |
Total other income (expense) | (205,429) | 1,267,952 | (439,198) | 492,911 |
Net loss | $ (6,168,725) | $ (691,081) | $ (14,832,899) | $ (6,841,545) |
Net loss per share of common stock, basic and diluted | $ (0.70) | $ (1.06) | $ (1.71) | $ (10.53) |
Weighted-average shares of common stock outstanding, basic and diluted | 8,756,393 | 649,721 | 8,685,818 | 649,721 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 9 Months Ended | |
Sep. 30, 2016 | Sep. 30, 2015 | |
Operating activities | ||
Net loss | $ (14,832,899) | $ (6,841,545) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 20,468 | 17,360 |
Stock-based compensation expense | 1,439,194 | 321,228 |
Non-cash interest expense | 134,096 | 204,759 |
Change in fair value of warrant liability, unit purchase option liability and investor rights obligation | 57,595 | (1,127,683) |
Changes in assets and liabilities: | ||
Grants receivable | (379,256) | |
Prepaid expenses and other assets | 191,527 | 255,248 |
Restricted cash | (79,051) | 58,333 |
Accounts payable | 109,908 | 318,218 |
Accrued expenses and other liabilities | 2,478,234 | 178,982 |
Net cash used in operating activities | (10,860,184) | (6,615,100) |
Investing activities | ||
Purchase of property and equipment | (25,646) | (19,984) |
Net cash used in investing activities | (25,646) | (19,984) |
Financing activities | ||
Proceeds from sale of shares under common stock purchase agreement | 1,000,000 | |
Principal payments on term debt | (2,459,493) | (1,023,798) |
Payment of deferred financing costs | (1,467) | (775,475) |
Net cash used in financing activities | (1,460,960) | (1,799,273) |
Decrease in cash and cash equivalents | (12,346,790) | (8,434,357) |
Cash and cash equivalents at beginning of period | 21,161,967 | 11,742,349 |
Cash and cash equivalents at end of period | 8,815,177 | 3,307,992 |
Supplemental disclosures of cash flow information | ||
Cash paid for interest | 287,841 | 434,971 |
Supplemental disclosures of noncash financing activities | ||
Accrued deferred financing costs | $ 101,728 | $ 1,104,316 |
Business
Business | 9 Months Ended |
Sep. 30, 2016 | |
BUSINESS | |
BUSINESS | 1. Business Cerecor Inc. (the “Company” or “Cerecor”) is a clinical‑stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders. The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to and developing certain product candidates, business planning and raising capital. Liquidity The Company's financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments that might be necessary should the Company be unable to continue to fund its operations. The Company has not generated any product revenues and has not yet achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and if achieved, could be sustained on a continuing basis. The Company has incurred recurring operating losses since inception. For the nine months ended September 30, 2016, the Company incurred a net loss of $14.8 million and generated negative cash flows from operations of $10.9 million. As of September 30, 2016, the Company had an accumulated deficit of $68.4 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the clinical development of its product candidates, its preclinical programs, business development and its organizational infrastructure. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy. The Company plans to meet its capital requirements primarily through a combination of equity and debt financings, collaborations, strategic alliances, federal and private grants, marketing, distribution or licensing arrangements and in the longer term, revenue from product sales to the extent its product candidates receive marketing approval and are commercialized. There can be no assurance, however, that the Company will be successful in obtaining financing at the level needed to sustain operations and develop its product candidates or on terms acceptable to the Company, or that the Company will obtain approvals necessary to market its products or achieve profitability or sustainable positive cash flow. The Company currently anticipates that current cash and cash equivalents will be sufficient to meet its anticipated cash requirements through the end of 2016. These factors raise significant doubt about the Company’s ability to continue as a going concern. The Company has the potential to raise additional cash through a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) as described in Note 8. |
Significant Accounting Policies
Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2016 | |
SIGNIFICANT ACCOUNTING POLICIES | |
SIGNIFICANT ACCOUNTING POLICIES | 2. Significant Accounting Policies Basis of Presentation The Company’s unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations and cash flows. The balance sheet at December 31, 2015 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited financial statements are read in conjunction with the December 31, 2015 audited financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, other comprehensive income and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals, the warrant liability and the unit purchase option liability. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Net Loss Per Share, Basic and Diluted Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted‑average number of shares of common stock outstanding during the period, excluding the dilutive effects, if any, of preferred stock, the investor rights obligation, warrants on preferred stock and common stock, stock options and unvested restricted stock. Diluted net loss per share of common stock is computed by dividing the net loss attributable to common stockholders by the sum of the weighted‑average number of shares of common stock outstanding during the period plus the potential dilutive effects of preferred stock, the investor rights obligation, warrants on preferred stock and common stock, stock options and unvested restricted stock outstanding during the period calculated in accordance with the treasury stock method, although these shares and options are excluded if their effect is anti‑dilutive. In addition, the Company analyzes the potential dilutive effect of any outstanding preferred stock, the investor rights obligation, and warrants on preferred stock and common stock under the “if‑converted” method when calculating diluted earnings per share, in which it is assumed that the outstanding security converts into common stock at the beginning of the period. Because the impact of these items is generally anti‑dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2016 and 2015. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value. Restricted Cash During 2013, the Company entered into a lease for new office space for its principal offices in Baltimore, Maryland. The Company initially provided the landlord with a letter of credit in the amount of $175,000 as security by the Company of the Company’s obligations under the lease. The letter of credit is supported by funds that are invested in a certificate of deposit. Provided there has been no event of default by the Company, the Company may request that the amount of the letter of credit be reduced by one‑third (approximately $58,000) at the end of each of the first three years of the lease term. At the expiration of the third year of the lease term, which will occur in the fourth quarter of 2016, the Company is required to deposit with the landlord the sum of $13,000 as a security deposit. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss. Debt Issuance Costs The Company may record debt and equity discounts in connection with raising funds through the issuance of convertible notes or equity instruments. These discounts may arise from (i) the receipt of proceeds less than the face value of the convertible notes or equity instruments, (ii) allocation of proceeds to beneficial conversion features and/or (iii) recording derivative liabilities related to embedded features. These costs are amortized over the life of the debt to interest expense utilizing the effective interest method. Property and Equipment Property and equipment consists of computers, office equipment, and furniture and is recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Property and equipment are depreciated on a straight‑line basis over their estimated useful lives. The Company uses a life of four years for computers and software, and five years for equipment and furniture. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. Grant Revenue Recognition The Company recognizes grant revenue when there is (i) reasonable assurance of compliance with the conditions of the grant and (ii) reasonable assurance that the grant will be received. In April 2016, the Company received a research and development grant from the National Institute on Drug Abuse at the National Institutes of Health to provide additional resources for the period from May 2016 through April 2017 for the Company’s ongoing Phase 2 clinical trial for CERC-501, “ A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior .” The amount of the award was $1.0 million. The Company recognizes revenue under grants in earnings on a systemic basis in the period the related expenditures for which the grants are intended to compensate are incurred. As such, the Company has recognized revenue in the amounts of $321,497 and $971,985 for the three and nine months ended September 30, 2016, respectively. As of September 30, 2016, the Company had received $592,729 of the revenue earned during the nine months ended September 30, 2016. Research and Development Research and development costs are expensed as incurred. These costs include, but are not limited to, employee‑related expenses, including salaries, benefits and stock‑based compensation of research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical trials and preclinical studies; the cost of acquiring, developing and manufacturing clinical trial materials; other supplies; facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities and insurance; and costs associated with preclinical activities and regulatory operations. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to the Company by its vendors, such as clinical research organizations, with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non‑owner sources. Comprehensive loss was equal to net loss for all periods presented. Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. The deferred tax asset primarily includes net operating loss and tax credit carryforwards, accrued expenses not currently deductible and the cumulative temporary differences related to certain research and patent costs, which have been charged to expense in the accompanying statements of operations but have been recorded as assets for income tax purposes. The portion of any deferred tax asset for which it is more likely than not that a tax benefit will not be realized must then be offset by recording a valuation allowance. A full valuation allowance has been established against all of the deferred tax assets as it is more likely than not that these assets will not be realized given the Company’s history of operating losses. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2016, the Company does not believe any material uncertain tax positions are present. Stock‑Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock‑based awards made to employees and non‑employees, including employee stock options, in the statements of operations. For stock options issued to employees and members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option using the Black‑Scholes option pricing model. The use of the Black‑Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk‑free interest rates and expected dividend yields of the common stock. For awards subject to service‑based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock‑based compensation expense, net of estimated forfeitures, equal to the grant date fair value of stock options on a straight‑line basis over the requisite service period, which is generally the vesting term. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For stock options issued to non‑employees, the Company initially measures the options at their grant date fair values and revalues as the underlying equity instruments vest and are recognized as expense over the earlier of the period ending with the performance commitment date or the date the services are completed in accordance with the provisions of ASC 718 and ASC 505‑50, Equity‑Based Payments to Non‑Employees (“ASC 505‑50”). Clinical Trial Expense Accruals As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third‑party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision‑making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the chief executive officer. The Company and the chief executive officer view the Company’s operations and manage its business as one operating segment. All long‑lived assets of the Company reside in the United States. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014‑09, Revenue From Contracts With Customers (“ASU 2014‑09”). Pursuant to this update, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue From Contracts With Customers (Topic 606) , which delays the effective date of ASU 2014-09 by one year. As a result, ASU 2014-09 will be effective for annual reporting periods beginning after December 15, 2017 with early adoption permitted for annual reporting periods beginning after December 15, 2016. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”) and ASU No. 2016-10, Revenue From Contracts With Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”), and in May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), each of which clarify the guidance in ASU 2014-09 and have the same effective date as the original standard. The Company has not yet determined the impact of adoption of ASU 2014-09, ASU 2016-08, ASU 2016-10, or ASU 2016-12 on the financial statements, although, the impact, if any, is not expected to be significant given the Company has not historically recognized significant amounts of revenue. In August 2014, the FASB issued ASU No. 2014‑15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The amendments in this update will explicitly require a company’s management to assess an entity’s ability to continue as a going concern within one year after the date the financial statements are issued, and to provide related footnote disclosures in certain circumstances. The new standard will be effective in the first annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the potential impact of the adoption of this standard, but believes its adoption will have no impact on its financial position, results of operations or cash flows. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This guidance revises existing practice related to accounting for leases under ASC 840, Leases (“ASC 840”) for both lessees and lessors. The new guidance in ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for nearly all leases (other than leases that meet the definition of a short-term lease). The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment such as for initial direct costs. For income statement purposes, the new standard retains a dual model similar to ASC 840, requiring leases to be classified as either operating leases or capital leases. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while capital leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The guidance is intended to simplify several areas of accounting for share-based compensation, including income tax impacts, classification on the statement of cash flows and forfeitures. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early application is permitted. The Company is currently evaluating the potential impact of the adoption of this standard, but believes its adoption will have no impact on its financial position, results of operations or cash flows. |
Net Loss Per Share Of Common St
Net Loss Per Share Of Common Stock, Basic And Diluted | 9 Months Ended |
Sep. 30, 2016 | |
NET LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED | |
NET LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED | 3. Net Loss Per Share of Common Stock, Basic and Diluted The following table sets forth the computation of basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2016 and 2015: Three Months Ended Nine Months Ended September 30, September 30, Net loss per share, basic and diluted calculation: 2016 2015 2016 2015 Net loss $ $ $ $ Weighted-average common shares outstanding Net loss per share, basic and diluted $ $ $ $ The following outstanding securities at September 30, 2016 and 2015 have been excluded from the computation of diluted weighted-average shares outstanding, as they would have been anti‑dilutive: September 30, September 30, 2016 2015 Series A convertible preferred stock — Series A-1 convertible preferred stock — Series B convertible preferred stock — Stock options Warrants on common stock Warrants on preferred stock — Investor rights obligation — Underwriters' unit purchase option — |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2016 | |
FAIR VALUE MEASUREMENTS | |
FAIR VALUE MEASUREMENTS | 4. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three‑level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows: · Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market. · Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model‑derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability. · Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. At September 30, 2016 and December 31, 2015, the Company’s financial instruments included cash and cash equivalents, restricted cash, accounts payable, accrued expenses and other current liabilities, long term debt, the term loan warrant liability and the underwriters’ unit purchase option liability. The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, restricted cash, accounts payable, and accrued expenses and other current liabilities approximate their respective fair values because of the short‑term nature of these accounts. The estimated fair value of the Company’s debt of $3.2 million as of September 30, 2016 was based on current interest rates for similar types of borrowings and is in Level 2 of the fair value hierarchy. The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company’s assets and liabilities that are measured at fair value on a recurring basis: September 30, 2016 Fair Value Measurements Using Quoted prices in Significant other Significant active markets for observable unobservable identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Investments in money market funds* $ $ — $ — Liabilities Warrant liability $ — $ — $ Unit purchase option liability $ — $ — $ December 31, 2015 Fair Value Measurements Using Quoted prices in Significant other Significant active markets for observable unobservable identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Investments in money market funds* $ $ — $ — Liabilities Warrant liability $ — $ — $ Unit purchase option liability $ — $ — $ * Level 3 Valuation The warrant liability (which relates to warrants to purchase shares of common stock as part of the term loan agreement) is marked‑to‑market each reporting period with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity. The fair value of the warrant liability is estimated using a Black‑Scholes option-pricing model. The significant assumptions used in preparing the option pricing model for valuing the warrant liability as of September 30, 2016, include (i) volatility of 85%, (ii) risk free interest rate of 1.02%, (iii) strike price ($8.40), (iv) fair value of common stock ($4.23), and (v) expected life of 4.1 years. The underwriters’ unit purchase option (the “UPO”) was issued to the underwriters of the Company’s initial public offering (“IPO”) and provides the underwriters the option to purchase up to a total of 40,000 units. The units underlying the UPO will be, immediately upon exercise, separated into shares of common stock, underwriters’ Class A warrants and underwriters’ Class B warrants (such warrants together referred to as the Underwriters’ Warrants). The Underwriters’ Warrants are warrants to purchase shares of common stock. The Company classifies the UPO as a liability as it is a freestanding marked-to-market derivative instrument that is precluded from being classified in stockholders’ equity. The UPO liability is marked‑to‑market each reporting period with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the UPO is exercised, expire or other facts and circumstances lead the UPO to be reclassified to stockholders’ equity. The fair value of the UPO liability is estimated using a Black-Scholes option-pricing model within a Monte Carlo simulation model framework. The significant assumptions used in preparing the simulation model for valuing the UPO as of September 30, 2016, include (i) volatility range of 65% to 95%, (ii) risk free interest rate range of 0.12% to 1.03%, (iii) unit strike price ($7.48), (iv) underwriters’ Class A warrant strike price ($5.23), (v) underwriters’ Class B warrant strike price ($4.49), (vi) fair value of underlying equity ($4.23), and (vii) optimal exercise point of immediately prior to the expiration of the underwriters’ Class B warrants, which occurs on April 20, 2017. The increase in the fair value of underlying equity was the primary driver of the increase in fair value of the UPO liability from $50,571 as of December 31, 2015 to $90,780 as of September 30, 2016. This $40,209 gain on the change in fair value of the UPO liability was recorded to other income in the accompanying statement of operations for the nine months ended September 30, 2016. The table presented below is a summary of changes of the Company’s Level 3 warrant liability and unit purchase option liability for the nine months ended September 30, 2016: Warrant Unit purchase liability option liability Total Balance at December 31, 2015 $ $ $ Change in fair value Balance at September 30, 2016 $ $ $ No other changes in valuation techniques or inputs occurred during the nine months ended September 30, 2016 and no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine months ended September 30, 2016. |
Accrued Expenses And Other Curr
Accrued Expenses And Other Current Liabilities | 9 Months Ended |
Sep. 30, 2016 | |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | 5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: September 30, December 31, 2016 2015 Compensation and benefits $ $ Research and development expenses General and administrative Accrued interest Total accrued expenses and other current liabilities $ $ |
Asset Acquisition And License A
Asset Acquisition And License Agreements | 9 Months Ended |
Sep. 30, 2016 | |
ASSET ACQUISITION AND LICENSE AGREEMENTS | |
ASSET ACQUISITION AND LICENSE AGREEMENTS | 6. License Agreements Lilly CERC-611 License On September 22, 2016, the Company entered into an exclusive license agreement with Eli Lilly and Company (“Lilly”) pursuant to which the Company received exclusive, global rights to develop and commercialize CERC-611, previously referred to as LY3130481, a potent and selective Transmembrane AMPA Receptor Regulatory Proteins (“TARP”) γ-8-dependent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (“AMPA”) receptor antagonist. The terms of the license agreement provide for an upfront payment of $2.0 million, of which $750,000 is due within 30 days of the effective date of the license agreement, and the remaining balance of $1.25 million is due after the first subject is dosed with CERC-611 in a multiple ascending dose study. The Company recorded the $2.0 upfront amount as a research and development expense in the accompanying statement of operations for the three and nine months ended September 30, 2016. Additional payments may be due upon achievement of development and commercialization milestones, including the first commercial sale. Upon commercialization, the Company is obligated to pay Lilly milestone payments and a royalty on net sales. Merck CERC-301 License In 2013, the Company entered into an exclusive license agreement with Merck & Co., Inc. (“Merck”) pursuant to which Merck granted the Company rights relating to certain small molecule compounds. In consideration of the license, the Company may be required to make initial payments totaling $1.5 million upon the achievement of certain milestones. Pursuant to the license agreement the Company paid an initial payment of $750,000, which was recorded as a research and development expense in the Company’s statement of operations for the year ended December 31, 2013, and upon achievement of acceptance by the United States Food and Drug Administration, or FDA, of Merck pre-clinical data and FDA approval of a Phase 3 clinical trial the Company will pay an additional $750,000. Additional payments may be due upon achievement of development and regulatory milestones, including the first commercial sale. Upon commercialization, the Company is obligated to pay Merck milestone payments and royalties on net sales. Lilly CERC-501 License In 2015, the Company acquired rights to CERC-501 through an exclusive, worldwide license from Lilly. Pursuant to the license agreement, the Company paid $750,000 to Lilly within 30 days of the execution of the license agreement, which was recorded as research and development expense in the accompanying statement of operations for the nine months ended September 30, 2015. Upon the Company undertaking a nine-month toxicology study of CERC-501 in non-human primates and delivering a final study report, the Company will be required to pay Lilly an additional $250,000. Additional payments may be due upon achievement of development and regulatory milestones, including the first commercial sale. Upon commercialization, the Company is obligated to pay Lilly milestone payments and royalties on net sales. Merck COMTi License In 2013, the Company entered into a separate exclusive license agreement with Merck pursuant to which Merck granted the Company certain rights in small molecule compounds which are known to inhibit the activity of COMT. In consideration of the license, the Company made a $200,000 upfront payment to Merck, which was recorded as research and development expense in the Company’s statement of operations for the year ended December 31, 2013. Additional payments may be due upon the achievement of development and regulatory milestones. Upon commercialization of a COMT product, the Company is required to pay Merck royalties on net sales. |
Term Loan
Term Loan | 9 Months Ended |
Sep. 30, 2016 | |
Term Loan. | |
Term Loan | 7. Term Loan In August 2014, the Company entered into a $7.5 million secured term loan from a finance company. The loan is secured by a lien on all of the Company’s assets, excluding intellectual property, which was subject to a negative pledge. The loan contains certain additional nonfinancial covenants. In connection with the loan agreement, the Company’s cash and investment accounts are subject to account control agreements with the finance company that give the finance company the right to assume control of the accounts in the event of a loan default. Loan defaults are defined in the loan agreement and include, among others, the finance company’s determination that there is a material adverse change in the Company’s operations. Interest on the loan is at a rate of the greater of 7.95%, or 7.95% plus the prime rate as reported in The Wall Street Journal minus 3.25%. The interest rate effective from loan inception to December 16, 2015 was 7.95%. Effective December 17, 2015, the prime rate as reported by The Wall Street Journal increased 0.25% resulting in an increase to the current interest rate, which was 8.20% as of September 30, 2016. The loan was interest‑only through May 2015, and is repayable in equal monthly payments of principal and interest of approximately $305,000 over 27 months, which began in June 2015. The loan matures in August 2017. Debt consisted of the following as of September 30, 2016 and December 31, 2015: September 30, December 31, 2016 2015 Term loan $ $ Less: debt discount Term Loan, net of debt discount Less: current portion, net of debt discount Long term debt, net of current portion and debt discount $ — $ Interest expense, which includes amortization of a discount and the accrual of a termination fee, was approximately $404,000 for the nine months ended September 30, 2016, in the accompanying statement of operations. In connection with the term loan, the Company issued warrants to purchase 625,208 shares of Series B convertible preferred stock at an exercise price of $0.2999 per share that is exercisable for a period ending in October 2020, which is five years following the closing of the Company’s IPO. Upon the closing of the Company’s IPO, these warrants became warrants to purchase 22,328 shares of common stock at an exercise price of $8.40 per share, in accordance with their terms. The Company’s warrant to purchase shares of Series B convertible preferred stock represented a freestanding financial instrument that was indexed to an obligation of the Company to repurchase its Series B convertible preferred stock by transferring assets and, therefore, met the criteria to be classified as a liability under FASB ASC 480, Distinguishing Liabilities from Equity . The Company records the warrant liability at its fair value using the Black‑Scholes option pricing model and revalues the warrant at each reporting date (see Note 4). |
Capital Structure
Capital Structure | 9 Months Ended |
Sep. 30, 2016 | |
CAPITAL STRUCTURE | |
CAPITAL STRUCTURE | 8. Capital Structure Initial Public Offering On October 20, 2015, the Company closed an IPO of its units. Each unit consisted of one share of common stock, one Class A warrant to purchase one share of common stock at an exercise price of $4.55 per share and one Class B warrant to purchase one-half share of common stock at an exercise price of $3.90 per full share (the “units”). The Class A warrants expire on October 20, 2018 and the Class B warrants expire on April 20, 2017. The closing of the IPO resulted in the sale of 4,000,000 units at an initial public offering price of $6.50 per unit for gross proceeds of $26.0 million. The net proceeds of the IPO, after underwriting discounts, commissions and expenses, and before offering expenses, to the Company were approximately $23.6 million. On November 13, 2015, the units separated into common stock, Class A warrants and Class B warrants and began trading separately on the NASDAQ Capital Market. On November 23, 2015, the underwriter of the IPO exercised its over-allotment option for 20,000 shares of common stock, 551,900 Class A warrants to purchase one share of common stock and 551,900 Class B warrants to purchase one-half share of common stock for additional gross proceeds of $135,319. The common stock and accompanying Class A warrants and Class B warrants have been classified to stockholders’ equity in the Company’s balance sheet. Underwriter’s Unit Purchase Option The underwriter of the IPO received, for $100 in the aggregate, a unit purchase option (the “UPO”) to purchase up to a total of 40,000 units (or 1% of the units sold in the IPO) exercisable at $7.48 per unit (or 115% of the public offering price per unit in the IPO). The units underlying the UPO will be, immediately upon exercise, separated into shares of common stock, underwriters’ Class A warrants and underwriters’ Class B warrants (such warrants together referred to as the “Underwriters’ Warrants”) such that, upon exercise, the holder of a UPO will not receive actual units but will instead receive the shares of common stock and Underwriters’ Warrants, to the extent that any portion of the Underwriters’ Warrants underlying such units have not otherwise expired. The exercise prices of the underwriters’ Class A warrants and underwriter’s Class B warrants underlying the UPO are $5.23 and $4.49, respectively. The UPO may be exercised for cash or on a cashless basis, at the holder’s option, and expires on October 14, 2020; provided, that, following the expiration of underwriters’ Class B warrants on April 20, 2017, the UPO will be exercisable only for shares of common stock and underwriters’ Class A warrants at an exercise price of $7.475 per unit; provided further, that, following the expiration of underwriters’ Class A warrants on October 20, 2018, the UPO will be exercisable only for shares of common stock at an exercise price of $7.47. The Company classified the UPO as a liability as it is a freestanding marked-to-market derivative instrument that is precluded from being classified in stockholders’ equity. The fair value of the UPO is re-measured each reporting period and the change in fair value is recognized in the statement of operations (see Note 4). The Aspire Capital Transaction On September 8, 2016, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, pursuant to which Aspire Capital committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the Purchase Agreement. Under the Purchase Agreement, on any trading day selected by the Company on which the closing price of the Company’s common stock exceeds $0.50, the Company may, in its sole discretion, present a purchase notice directing Aspire Capital to purchase up to 50,000 shares of common stock per day, up to $15.0 million of the Company’s common stock in the aggregate at a per share price calculated by references to the prevailing market price of the Company’s common stock. Upon execution of the Purchase Agreement, the Company issued and sold to Aspire Capital 250,000 shares of common stock at a price per share of $4.00, for gross proceeds of $1.0 million, and concurrently entered into a registration rights agreement with Aspire Capital registering the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the Purchase Agreement. Additionally, as consideration for Aspire Capital entering into the Purchase Agreement, the Company issued 175,000 shares of common stock as a commitment fee. The net proceeds of the Aspire Capital transaction, after offering expenses, to the Company were approximately $900,000 for the three and nine months ended September 30, 2016. As of September 30, 2016, the Company had sold 250,000 shares of common stock to Aspire Capital under the Purchase Agreement. Subsequent to September 30, 2016, the Company sold an additional 188,998 shares of common stock to Aspire Capital under the terms of the Purchase Agreement for gross proceeds of approximately $700,000. As of the date of this filing, the Company may issue to Aspire Capital under the Purchase Agreement 1,115,165 shares of common stock. Common Stock Warrants At September 30, 2016, the following common stock purchase warrants were outstanding: Number of shares Exercise price Expiration underlying warrants per share date 109,976 $ February 2017 29,260 $ February 2017 90,529 $ March 2017 29,557 $ March 2017 130,233 $ April 2017 2,275,950 $ April 2017 20,000* $ April 2017 14,284 $ July 2017 80,966 $ August 2018 4,551,900 $ October 2018 40,000* $ October 2018 3,571 $ December 2018 22,328* $ October 2020 2,380 $ May 2022 7,400,934 * |
Stock Based Compensation
Stock Based Compensation | 9 Months Ended |
Sep. 30, 2016 | |
Stock-Based Compensation | |
STOCK BASED COMPENSATION | 9. Stock-Based Compensation 2016 Equity Incentive Plan On April 5, 2016, the Company’s board of directors adopted the 2016 Equity Incentive Plan (the “2016 Plan”) as the successor to the 2015 Omnibus Plan (the “2015 Plan”). The 2016 Plan was approved by the Company’s stockholders and became effective on May 18, 2016 (the “2016 Plan Effective Date”). As of the 2016 Plan Effective Date, no additional grants will be made under the 2015 Plan or the 2011 Stock Incentive Plan (the “2011 Plan”), which was previously succeeded by the 2015 Plan effective October 13, 2015. Outstanding grants under the 2015 Plan and 2011 Plan will continue in effect according to their terms as in effect under the applicable plan. Upon the 2016 Plan Effective Date, the 2016 Plan reserved and authorized up to 600,000 additional shares of common stock for issuance, as well as 464,476 unallocated shares remaining available for grant of new awards under the 2015 Plan. During the term of the 2016 Plan, the share reserve will automatically increase on the first trading day in January of each calendar year, beginning in 2017, by an amount equal to 4% of the total number of outstanding shares of common stock of the Company on the last trading day in December of the prior calendar year. As of September 30, 2016, there were 691,987 shares available for future issuance under the 2016 Plan. The estimated grant date fair market value of the Company’s stock‑based awards is amortized ratably over the employees’ service periods, which is the period in which the awards vest. Stock‑based compensation expense recognized for the three and nine months ended September 30, 2016 and 2015 was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Research and development $ $ $ $ General and administrative Total stock-based compensation $ $ $ $ During the first quarter of 2016, the Company modified stock options of its former chief executive officer by extending the life of the awards, which were set to expire in March 2016, to coincide with their original life. This modification resulted in the recording of $781,266 of compensation expense, which is included in general and administrative expenses for the nine months ended September 30, 2016 in the accompanying statement of operations. A summary of option activity for the nine months ended September 30, 2016 is as follows: Options Outstanding Weighted average Fair value of remaining Number of Weighted‑average options contractual term shares exercise price granted (in years) Balance, December 31, 2015 $ Granted $ $ Balance, September 30, 2016 $ Vested or expected to vest at September 30, 2016 $ Exercisable at September 30, 2016 $ Employee Stock Purchase Plan On April 5, 2016, the Company’s board of directors approved the 2016 Employee Stock Purchase Plan (the “ESPP”). The ESPP was approved by the Company’s stockholders and became effective on May 18, 2016 (the “ESPP Effective Date”). Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company’s board of directors. Under the ESPP, eligible employees may purchase stock at 85% of the lower of the fair market value of a share of the Company’s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to 15% of their earnings during the offering period. The Company’s board of directors may establish a maximum number of shares of the Company’s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 of the fair market value of the Company’s common stock for each calendar year in which such right is outstanding. Upon the ESPP Effective Date, the ESPP reserved and authorized up to 500,000 shares of common stock for issuance. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP shall automatically increase by a number equal to the lesser of (i) 1% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, and (ii) 500,000 shares of the Company’s common stock, or (iii) a number of shares of the Company’s common stock as determined by the Company’s board of directors or compensation committee. As of September 30, 2016, 500,000 shares remained available for issuance. In accordance with the guidance in ASC 718-50, Employee Share Purchase Plans (“ASC 718-50”), the ability to purchase shares of the Company’s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $36,690 and $43,213 for the three and nine months ended September 30, 2016, respectively. |
Significant Accounting Polici15
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2016 | |
SIGNIFICANT ACCOUNTING POLICIES | |
Basis of Presentation | Basis of Presentation The Company’s unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations and cash flows. The balance sheet at December 31, 2015 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited financial statements are read in conjunction with the December 31, 2015 audited financial statements. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, other comprehensive income and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals, the warrant liability and the unit purchase option liability. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. |
Net Loss Per Share, Basic and Diluted | Net Loss Per Share, Basic and Diluted Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted‑average number of shares of common stock outstanding during the period, excluding the dilutive effects, if any, of preferred stock, the investor rights obligation, warrants on preferred stock and common stock, stock options and unvested restricted stock. Diluted net loss per share of common stock is computed by dividing the net loss attributable to common stockholders by the sum of the weighted‑average number of shares of common stock outstanding during the period plus the potential dilutive effects of preferred stock, the investor rights obligation, warrants on preferred stock and common stock, stock options and unvested restricted stock outstanding during the period calculated in accordance with the treasury stock method, although these shares and options are excluded if their effect is anti‑dilutive. In addition, the Company analyzes the potential dilutive effect of any outstanding preferred stock, the investor rights obligation, and warrants on preferred stock and common stock under the “if‑converted” method when calculating diluted earnings per share, in which it is assumed that the outstanding security converts into common stock at the beginning of the period. Because the impact of these items is generally anti‑dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2016 and 2015. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value. |
Restricted Cash | Restricted Cash During 2013, the Company entered into a lease for new office space for its principal offices in Baltimore, Maryland. The Company initially provided the landlord with a letter of credit in the amount of $175,000 as security by the Company of the Company’s obligations under the lease. The letter of credit is supported by funds that are invested in a certificate of deposit. Provided there has been no event of default by the Company, the Company may request that the amount of the letter of credit be reduced by one‑third (approximately $58,000) at the end of each of the first three years of the lease term. At the expiration of the third year of the lease term, which will occur in the fourth quarter of 2016, the Company is required to deposit with the landlord the sum of $13,000 as a security deposit. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss. |
Debt Issuance Costs | Debt Issuance Costs The Company may record debt and equity discounts in connection with raising funds through the issuance of convertible notes or equity instruments. These discounts may arise from (i) the receipt of proceeds less than the face value of the convertible notes or equity instruments, (ii) allocation of proceeds to beneficial conversion features and/or (iii) recording derivative liabilities related to embedded features. These costs are amortized over the life of the debt to interest expense utilizing the effective interest method. |
Property and Equipment | Property and Equipment Property and equipment consists of computers, office equipment, and furniture and is recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Property and equipment are depreciated on a straight‑line basis over their estimated useful lives. The Company uses a life of four years for computers and software, and five years for equipment and furniture. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. Grant Revenue Recognition The Com |
Grant Revenue Recognition | Grant Revenue Recognition The Company recognizes grant revenue when there is (i) reasonable assurance of compliance with the conditions of the grant and (ii) reasonable assurance that the grant will be received. In April 2016, the Company received a research and development grant from the National Institute on Drug Abuse at the National Institutes of Health to provide additional resources for the period from May 2016 through April 2017 for the Company’s ongoing Phase 2 clinical trial for CERC-501, “ A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior .” The amount of the award was $1.0 million. The Company recognizes revenue under grants in earnings on a systemic basis in the period the related expenditures for which the grants are intended to compensate are incurred. As such, the Company has recognized revenue in the amounts of $321,497 and $971,985 for the three and nine months ended September 30, 2016, respectively. As of September 30, 2016, the Company had received $592,729 of |
Research and Development | Research and Development Research and development costs are expensed as incurred. These costs include, but are not limited to, employee‑related expenses, including salaries, benefits and stock‑based compensation of research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical trials and preclinical studies; the cost of acquiring, developing and manufacturing clinical trial materials; other supplies; facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities and insurance; and costs associated with preclinical activities and regulatory operations. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to the Company by its vendors, such as clinical research organizations, with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non‑owner sources. Comprehensive loss was equal to net loss for all periods presented. |
Income Taxes | Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. The deferred tax asset primarily includes net operating loss and tax credit carryforwards, accrued expenses not currently deductible and the cumulative temporary differences related to certain research and patent costs, which have been charged to expense in the accompanying statements of operations but have been recorded as assets for income tax purposes. The portion of any deferred tax asset for which it is more likely than not that a tax benefit will not be realized must then be offset by recording a valuation allowance. A full valuation allowance has been established against all of the deferred tax assets as it is more likely than not that these assets will not be realized given the Company’s history of operating losses. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2016, the Company does not believe any material uncertain tax positions are present. |
Stock-Based Compensation | Stock‑Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock‑based awards made to employees and non‑employees, including employee stock options, in the statements of operations. For stock options issued to employees and members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option using the Black‑Scholes option pricing model. The use of the Black‑Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk‑free interest rates and expected dividend yields of the common stock. For awards subject to service‑based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock‑based compensation expense, net of estimated forfeitures, equal to the grant date fair value of stock options on a straight‑line basis over the requisite service period, which is generally the vesting term. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For stock options issued to non‑employees, the Company initially measures the options at their grant date fair values and revalues as the underlying equity instruments vest and are recognized as expense over the earlier of the period ending with the performance commitment date or the date the services are completed in accordance with the provisions of ASC 718 and ASC 505‑50, Equity‑Based Payments to Non‑Employees (“ASC 505‑50”). |
Clinical Trial Expense Accruals | Clinical Trial Expense Accruals As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third‑party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. |
Segment Information | Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision‑making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the chief executive officer. The Company and the chief executive officer view the Company’s operations and manage its business as one operating segment. All long‑lived assets of the Company reside in the United States. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014‑09, Revenue From Contracts With Customers (“ASU 2014‑09”). Pursuant to this update, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue From Contracts With Customers (Topic 606) , which delays the effective date of ASU 2014-09 by one year. As a result, ASU 2014-09 will be effective for annual reporting periods beginning after December 15, 2017 with early adoption permitted for annual reporting periods beginning after December 15, 2016. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”) and ASU No. 2016-10, Revenue From Contracts With Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”), and in May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), each of which clarify the guidance in ASU 2014-09 and have the same effective date as the original standard. The Company has not yet determined the impact of adoption of ASU 2014-09, ASU 2016-08, ASU 2016-10, or ASU 2016-12 on the financial statements, although, the impact, if any, is not expected to be significant given the Company has not historically recognized significant amounts of revenue. In August 2014, the FASB issued ASU No. 2014‑15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The amendments in this update will explicitly require a company’s management to assess an entity’s ability to continue as a going concern within one year after the date the financial statements are issued, and to provide related footnote disclosures in certain circumstances. The new standard will be effective in the first annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the potential impact of the adoption of this standard, but believes its adoption will have no impact on its financial position, results of operations or cash flows. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This guidance revises existing practice related to accounting for leases under ASC 840, Leases (“ASC 840”) for both lessees and lessors. The new guidance in ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for nearly all leases (other than leases that meet the definition of a short-term lease). The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment such as for initial direct costs. For income statement purposes, the new standard retains a dual model similar to ASC 840, requiring leases to be classified as either operating leases or capital leases. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while capital leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The guidance is intended to simplify several areas of accounting for share-based compensation, including income tax impacts, classification on the statement of cash flows and forfeitures. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early application is permitted. The Company is currently evaluating the potential impact of the adoption of this standard, but believes its adoption will have no impact on its financial position, results of operations or cash flows. |
Net Loss Per Share Of Common 16
Net Loss Per Share Of Common Stock, Basic And Diluted (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
NET LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED | |
Schedule of the computation of basic and diluted net loss per share of Common Stock | Three Months Ended Nine Months Ended September 30, September 30, Net loss per share, basic and diluted calculation: 2016 2015 2016 2015 Net loss $ $ $ $ Weighted-average common shares outstanding Net loss per share, basic and diluted $ $ $ $ |
Schedule of anti-dilutive securities excluded from computation of diluted weighted shares outstanding | September 30, September 30, 2016 2015 Series A convertible preferred stock — Series A-1 convertible preferred stock — Series B convertible preferred stock — Stock options Warrants on common stock Warrants on preferred stock — Investor rights obligation — Underwriters' unit purchase option — |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
FAIR VALUE MEASUREMENTS | |
Schedule of assets and liabilities that are measured at fair value on a recurring basis | September 30, 2016 Fair Value Measurements Using Quoted prices in Significant other Significant active markets for observable unobservable identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Investments in money market funds* $ $ — $ — Liabilities Warrant liability $ — $ — $ Unit purchase option liability $ — $ — $ December 31, 2015 Fair Value Measurements Using Quoted prices in Significant other Significant active markets for observable unobservable identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Investments in money market funds* $ $ — $ — Liabilities Warrant liability $ — $ — $ Unit purchase option liability $ — $ — $ * |
Summary of changes in the fair value of the Level 3 valuation for the Warrant Liability and the Investor Rights Obligation | Warrant Unit purchase liability option liability Total Balance at December 31, 2015 $ $ $ Change in fair value Balance at September 30, 2016 $ $ $ |
Accrued Expenses And Other Cu18
Accrued Expenses And Other Current Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | |
Schedule of accrued expenses and other current liabilities | September 30, December 31, 2016 2015 Compensation and benefits $ $ Research and development expenses General and administrative Accrued interest Total accrued expenses and other current liabilities $ $ |
Term Loan (Tables)
Term Loan (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
Term Loan. | |
Schedule of debt | September 30, December 31, 2016 2015 Term loan $ $ Less: debt discount Term Loan, net of debt discount Less: current portion, net of debt discount Long term debt, net of current portion and debt discount $ — $ |
Stock Based Compensation (Table
Stock Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
Stock-Based Compensation | |
Schedule of stock-based compensation expense | Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Research and development $ $ $ $ General and administrative Total stock-based compensation $ $ $ $ |
Summary of option activity | Options Outstanding Weighted average Fair value of remaining Number of Weighted‑average options contractual term shares exercise price granted (in years) Balance, December 31, 2015 $ Granted $ $ Balance, September 30, 2016 $ Vested or expected to vest at September 30, 2016 $ Exercisable at September 30, 2016 $ |
Commitments And Contingencies (
Commitments And Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
COMMITMENTS AND CONTINGENCIES | |
Schedule of future lease obligations | Year ending December 31, 2016* $ 2017 2018 $ * |
Business (Details)
Business (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | Dec. 31, 2015 | |
BUSINESS | |||||
Net loss | $ (6,168,725) | $ (691,081) | $ (14,832,899) | $ (6,841,545) | |
Cash flows from operations | (10,860,184) | $ (6,615,100) | |||
Accumulated deficit | $ (68,396,379) | $ (68,396,379) | $ (53,563,480) |
Significant Accounting Polici23
Significant Accounting Policies (Details) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2016USD ($)$ / shares | Sep. 30, 2015$ / shares | Jun. 30, 2016USD ($) | Sep. 30, 2016USD ($)item$ / shares | Sep. 30, 2015$ / shares | Dec. 31, 2013USD ($) | |
Net Loss Per Share of Common Stock, Basic and Diluted | ||||||
Difference between basic net loss per share and diluted net loss per share | $ / shares | $ 0 | $ 0 | $ 0 | $ 0 | ||
Restricted Cash [Abstract] | ||||||
Certificate of deposit supporting lease obligation | $ 175,000 | |||||
Annual reduction permitted or requested in restricted cash, as a percent | 33.00% | 33.00% | ||||
Annual reduction permitted or requested in restricted cash | $ 58,000 | $ 58,000 | ||||
Number of periods reduction may be allowed | 3 years | |||||
Security deposit required, end of third year | $ 13,000 | |||||
Grant Revenue Recognition | ||||||
Revenue recognized on grant | $ 321,497 | $ 971,985 | ||||
Segment information | ||||||
Number of Operating Segments | item | 1 | |||||
Computers and software | ||||||
Property and Equipment | ||||||
Property, Plant and Equipment, Useful Life | 4 years | |||||
Equipment [Member] | ||||||
Property and Equipment | ||||||
Property, Plant and Equipment, Useful Life | 5 years | |||||
Furniture and Fixtures [Member] | ||||||
Property and Equipment | ||||||
Property, Plant and Equipment, Useful Life | 5 years | |||||
National Institute On Drug Abuse (Member) | ||||||
Grant Revenue Recognition | ||||||
Research and development grant award | $ 1,000,000 | |||||
Revenue recognized on grant | $ 321,497 | 971,985 | ||||
Proceeds received for revenue earned under grant | $ 592,729 |
Net Loss Per Share Of Common 24
Net Loss Per Share Of Common Stock, Basic And Diluted - 10Q (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | |
NET LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED | ||||
Net loss | $ (6,168,725) | $ (691,081) | $ (14,832,899) | $ (6,841,545) |
Weighted-average shares of common stock outstanding, basic and diluted | 8,756,393 | 649,721 | 8,685,818 | 649,721 |
Net loss per share, basic and diluted | $ (0.70) | $ (1.06) | $ (1.71) | $ (10.53) |
Net Loss Per Share Of Common 25
Net Loss Per Share Of Common Stock, Basic And Diluted - Anti-dilutive Securities (Details) - shares | 9 Months Ended | |
Sep. 30, 2016 | Sep. 30, 2015 | |
Series A Convertible preferred stock | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 31,116,391 | |
Series A-1 Convertible preferred stock | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 9,074,511 | |
Series B convertible preferred stock | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 58,948,735 | |
Stock Options | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 1,828,441 | 510,884 |
Warrants on Common Stock | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 7,400,934 | 681,858 |
Warrants on Preferred Stock | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 625,208 | |
Investor Rights Obligation | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 53,351,117 | |
Underwriters Unit Purchase Option | ||
Anti-dilutive securities | ||
Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding | 40,000 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - USD ($) | Sep. 30, 2016 | Dec. 31, 2015 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ||
Estimated fair value of debt | $ 3,200,000 | |
Recurring basis | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ||
Investments in money market funds | 8,661,483 | $ 21,122,553 |
Recurring basis | Level 3 | Warrants on Preferred Stock | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ||
Liabilities and obligations | 44,992 | 27,606 |
Recurring basis | Level 3 | Equity Unit Purchase Option | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ||
Liabilities and obligations | $ 90,780 | $ 50,571 |
Fair Value Measurements - Assum
Fair Value Measurements - Assumptions, RF (Details) | 9 Months Ended |
Sep. 30, 2016USD ($)item$ / sharesshares | |
Summary of changes in the fair value of the Level 3 valuation for the Warrant Liability and the Investor Rights Obligation | |
Number of changes in valuation techniques | item | 0 |
Amount of transfers of assets from level 1 to level 2 | $ 0 |
Amount of transfers of assets from level 2 to level 1 | $ 0 |
Common stock warrants | |
Level 3 Valuation | |
Number of shares available under warrant | shares | 40,000 |
Level 3 | |
Summary of changes in the fair value of the Level 3 valuation for the Warrant Liability and the Investor Rights Obligation | |
Beginning balance | $ 78,177 |
Change in fair value | 57,595 |
Ending balance | $ 135,772 |
Warrants on Preferred Stock | Level 3 | |
Level 3 Valuation | |
Volatility | 85.00% |
Risk free interest rate | 1.02% |
Strike price | $ / shares | $ 8.40 |
Fair value of stock price | $ / shares | $ 4.23 |
Expected life | 4 years 1 month 6 days |
Summary of changes in the fair value of the Level 3 valuation for the Warrant Liability and the Investor Rights Obligation | |
Beginning balance | $ 27,606 |
Change in fair value | 17,386 |
Ending balance | 44,992 |
Equity Unit Purchase Option | Other Nonoperating Income (Expense) | |
Summary of changes in the fair value of the Level 3 valuation for the Warrant Liability and the Investor Rights Obligation | |
Change in fair value | $ 40,209 |
Equity Unit Purchase Option | Level 3 | |
Level 3 Valuation | |
Strike price | $ / shares | $ 7.48 |
Fair value of stock price | $ / shares | $ 4.23 |
Summary of changes in the fair value of the Level 3 valuation for the Warrant Liability and the Investor Rights Obligation | |
Beginning balance | $ 50,571 |
Change in fair value | 40,209 |
Ending balance | $ 90,780 |
Equity Unit Purchase Option | Level 3 | Class A Warrant | |
Level 3 Valuation | |
Strike price | $ / shares | $ 5.23 |
Equity Unit Purchase Option | Level 3 | Class B Warrant | |
Level 3 Valuation | |
Strike price | $ / shares | $ 4.49 |
Equity Unit Purchase Option | Level 3 | Minimum | |
Level 3 Valuation | |
Volatility | 65.00% |
Risk free interest rate | 0.12% |
Equity Unit Purchase Option | Level 3 | Maximum | |
Level 3 Valuation | |
Volatility | 95.00% |
Risk free interest rate | 1.03% |
Accrued Expenses And Other Cu28
Accrued Expenses And Other Current Liabilities (Details) - USD ($) | Sep. 30, 2016 | Dec. 31, 2015 |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | ||
Compensation and benefits | $ 849,859 | $ 1,128,073 |
Research and development expenses | 2,166,342 | 464,719 |
General and administrative | 156,021 | 253,132 |
Accrued interest | 188,967 | 39,534 |
Total accrued expenses and other current liabilities | $ 3,361,189 | $ 1,885,458 |
Asset Acquisition And License29
Asset Acquisition And License Agreements (Details) - USD ($) | Sep. 22, 2016 | Sep. 30, 2016 | Sep. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2013 |
Merck | CERC-301 | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Total Cost of License Agreement | $ 1,500,000 | ||||
Other Commitment | 750,000 | ||||
Merck | CERC-301 | Research and development expense | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Initial license acquisition payments | 750,000 | ||||
Merck | COMT Inhibitor | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Initial license acquisition payments | $ 200,000 | ||||
Lilly | CERC-611 | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Initial license acquisition payments | $ 2,000,000 | ||||
Upfront payment due within 30 days | 750,000 | ||||
Upfront payment due after first subject dosed | $ 1,250,000 | ||||
Lilly | CERC-611 | Research and development expense | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Initial license acquisition payments | $ 2,000,000 | $ 2,000,000 | |||
Lilly | CERC-501 | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Term within execution of license agreement | 30 days | ||||
Other Commitment | $ 250,000 | ||||
Term of the study | 9 months | ||||
Lilly | CERC-501 | Research and development expense | |||||
Asset Acquisition And License Agreement [Line Items] | |||||
Initial license acquisition payments | $ 750,000 |
Term Loan (Details)
Term Loan (Details) - USD ($) | Dec. 17, 2015 | Aug. 31, 2014 | Sep. 30, 2016 | Dec. 16, 2015 | Dec. 31, 2015 | Oct. 20, 2015 |
Debt | ||||||
Term loan | $ 3,228,763 | $ 5,688,256 | ||||
Less: debt discount | (38,970) | (126,700) | ||||
Term Loan, net of debt discount | 3,189,793 | 5,561,556 | ||||
Less: current portion, net of debt discount | (3,189,793) | (3,208,074) | ||||
Long term debt, net of current portion and discount | 2,353,482 | |||||
Long-term Debt, Fiscal Year Maturity | ||||||
Term loan | $ 3,228,763 | $ 5,688,256 | ||||
Common stock warrants | ||||||
Debt | ||||||
Number of shares available under warrant | 40,000 | |||||
Term Loan, Long-Term | ||||||
Term Loan | ||||||
Face amount | $ 7,500,000 | |||||
Current interest rate | 8.20% | |||||
Monthly payments of principal and interest | $ 305,000 | |||||
Monthly payments of principal and interest, term | 27 months | |||||
Debt | ||||||
Interest expense including amortization of discount and accrual of termination fee | $ 404,000 | |||||
Term Loan, Long-Term | Series B convertible preferred stock warrants | ||||||
Debt | ||||||
Number of shares available under warrant | 625,208 | |||||
Exercise price per share (in dollars per share) | $ 0.2999 | |||||
Exercisable term following an IPO | 5 years | |||||
Term Loan, Long-Term | Common stock warrants | ||||||
Debt | ||||||
Number of shares available under warrant | 22,328 | |||||
Exercise price per share (in dollars per share) | $ 8.40 | |||||
Term Loan, Long-Term | Prime rate | ||||||
Term Loan | ||||||
Debt Instrument, Interest Rate, Increase (Decrease) | 0.25% | |||||
Term loan | Term Loan, Long-Term | ||||||
Term Loan | ||||||
Interest rate, maximum | 7.95% | |||||
Debt Instrument, Interest Rate During Period | 7.95% | |||||
Term loan | Term Loan, Long-Term | Prime rate | ||||||
Term Loan | ||||||
Margin on interest rate, deducted from basis | 3.25% |
Capital Structure - IPO (Detail
Capital Structure - IPO (Details) - USD ($) | Nov. 23, 2015 | Oct. 20, 2015 | Sep. 30, 2016 | Dec. 31, 2015 |
Common Stock | ||||
Common stock, Shares authorized | 200,000,000 | 200,000,000 | ||
Common stock, par value | $ 0.001 | $ 0.001 | ||
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | ||
Common stock outstanding | 9,075,143 | 8,650,143 | ||
Preferred stock outstanding | 0 | 0 | ||
IPO | Capital Unit | ||||
Initial Public Offering [Abstract] | ||||
Shares issued | 4,000,000 | |||
Share Price | $ 6.50 | |||
Gross proceeds | $ 26,000,000 | |||
Net proceeds from IPO | 23,600,000 | |||
Over-Allotment Option | ||||
Initial Public Offering [Abstract] | ||||
Gross proceeds | $ 135,319 | |||
Underwriters Unit Purchase Option | Capital Unit | ||||
Underwriter's Unit Purchase Option [Abstract] | ||||
Proceeds from unit purchase option | $ 100 | |||
Units available, as a percentage of units sold | 1.00% | |||
Equity purchase option unit, exercise price per unit | $ 7.48 | |||
Equity purchase option unit, exercise price as percent of IPO price | 115.00% | |||
Underwriters Unit Purchase Option | Capital Unit | Maximum | ||||
Underwriter's Unit Purchase Option [Abstract] | ||||
Number of units available under the option | 40,000 | |||
Class A Warrant | ||||
Initial Public Offering [Abstract] | ||||
Number of shares per warrant | 1 | |||
Class A Warrant | IPO | ||||
Initial Public Offering [Abstract] | ||||
Number of Equity Instruments Included in a Unit | 1 | |||
Exercise price per share (in dollars per share) | $ 4.55 | |||
Class A Warrant | Over-Allotment Option | ||||
Initial Public Offering [Abstract] | ||||
Shares issued | 551,900 | |||
Class A Warrant | Underwriters Unit Purchase Option | ||||
Initial Public Offering [Abstract] | ||||
Exercise price per share (in dollars per share) | 5.23 | |||
Underwriter's Unit Purchase Option [Abstract] | ||||
Equity purchase option, unit exercise price after first warrant expiration | 7.475 | |||
Equity purchase option, unit exercise price after second warrant expiration | $ 7.47 | |||
Class B Warrant | IPO | ||||
Initial Public Offering [Abstract] | ||||
Number of Equity Instruments Included in a Unit | 1 | |||
Exercise price per share (in dollars per share) | $ 3.90 | |||
Class B Warrant | Over-Allotment Option | ||||
Initial Public Offering [Abstract] | ||||
Shares issued | 551,900 | |||
Class B Warrant | Underwriters Unit Purchase Option | ||||
Initial Public Offering [Abstract] | ||||
Exercise price per share (in dollars per share) | $ 4.49 | |||
Common Stock | IPO | ||||
Initial Public Offering [Abstract] | ||||
Number of Equity Instruments Included in a Unit | 1 | |||
Common Stock | Over-Allotment Option | ||||
Initial Public Offering [Abstract] | ||||
Shares issued | 20,000 | |||
Common Stock | Class A Warrant | Over-Allotment Option | ||||
Initial Public Offering [Abstract] | ||||
Number of shares per warrant | 1 | |||
Common Stock | Class B Warrant | ||||
Initial Public Offering [Abstract] | ||||
Number of shares per warrant | 0.5 | |||
Common Stock | Class B Warrant | Over-Allotment Option | ||||
Initial Public Offering [Abstract] | ||||
Number of shares per warrant | 0.5 |
Capital Structure - Aspire Capi
Capital Structure - Aspire Capital Transaction (Details) - USD ($) | Oct. 01, 2016 | Sep. 08, 2016 | Sep. 30, 2016 | Sep. 30, 2016 | Dec. 31, 2015 |
The Aspire Capital Transaction | |||||
Number of shares sold under purchase agreement | 9,075,143 | 9,075,143 | 8,650,143 | ||
Net proceeds of transaction, after offering expenses | $ 1,000,000 | ||||
Aspire Capital | Common Stock Purchase Agreement | |||||
The Aspire Capital Transaction | |||||
Maximum value of common stock purchases committed to by counterparty | $ 15,000,000 | ||||
Term of the common stock purchase agreement | 30 months | ||||
Threshold price per common stock on any trading day to present notice for purchase of common stock | $ 0.50 | ||||
Number of shares sold under purchase agreement | 250,000 | 250,000 | 250,000 | ||
Price per share | $ 4 | ||||
Gross proceeds | $ 1,000,000 | ||||
Number of share of common stock issued as commitment fee | 175,000 | ||||
Net proceeds of transaction, after offering expenses | $ 900,000 | $ 900,000 | |||
Aspire Capital | Common Stock Purchase Agreement | Maximum | |||||
The Aspire Capital Transaction | |||||
Number of common stock issued per day on achieving threshold price per common stock | 50,000 | ||||
Aspire Capital | Forecast | Common Stock Purchase Agreement | |||||
The Aspire Capital Transaction | |||||
Number of shares sold under purchase agreement | 1,115,165 | 1,115,165 | |||
Aspire Capital | Subsequent events | Common Stock Purchase Agreement | |||||
The Aspire Capital Transaction | |||||
Number of shares sold under purchase agreement | 188,998 | ||||
Gross proceeds | $ 700,000 |
Capital Structure - Common Stoc
Capital Structure - Common Stock Warrants (Details) | Sep. 30, 2016$ / sharesshares |
Common Stock | |
Warrants | |
Number of shares underlying warrants | 7,400,934 |
Common stock warrants | |
Warrants | |
Number of shares underlying warrants | 40,000 |
Common stock warrants, expiration date of February 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 109,976 |
Exercise price per share (in dollars per share) | $ / shares | $ 28 |
Common stock warrants, expiration date of February 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 29,260 |
Exercise price per share (in dollars per share) | $ / shares | $ 14 |
Common stock warrants, expiration date of March 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 90,529 |
Exercise price per share (in dollars per share) | $ / shares | $ 28 |
Common stock warrants, expiration date of March 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 29,557 |
Exercise price per share (in dollars per share) | $ / shares | $ 14 |
Common stock warrants, expiration date of April 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 130,233 |
Exercise price per share (in dollars per share) | $ / shares | $ 28 |
Common stock warrants, expiration date of April 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 2,275,950 |
Exercise price per share (in dollars per share) | $ / shares | $ 3.90 |
Common stock warrants, expiration date of April 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 20,000 |
Exercise price per share (in dollars per share) | $ / shares | $ 4.49 |
Common stock warrants, expiration date of July 2017 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 14,284 |
Exercise price per share (in dollars per share) | $ / shares | $ 28 |
Common stock warrants, expiration date of August 2018 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 80,966 |
Exercise price per share (in dollars per share) | $ / shares | $ 28 |
Common stock warrants, expiration date of October 2018 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 4,551,900 |
Exercise price per share (in dollars per share) | $ / shares | $ 4.55 |
Common stock warrants, expiration date of October 2018 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 40,000 |
Exercise price per share (in dollars per share) | $ / shares | $ 5.23 |
Common stock warrants, expiration date of December 2018 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 3,571 |
Exercise price per share (in dollars per share) | $ / shares | $ 28 |
Common stock warrants, expiration date of October 2020 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 22,328 |
Exercise price per share (in dollars per share) | $ / shares | $ 8.40 |
Common stock warrants, expiration date of May 2022 | Common Stock | |
Warrants | |
Number of shares underlying warrants | 2,380 |
Exercise price per share (in dollars per share) | $ / shares | $ 8.68 |
Stock Based Compensation - 2016
Stock Based Compensation - 2016 Equity Incentive Plan (Details) | May 18, 2016itemshares | Sep. 30, 2016USD ($)$ / sharesshares | Sep. 30, 2015USD ($) | Sep. 30, 2016USD ($)$ / sharesshares | Sep. 30, 2015USD ($) |
Total stock-based compensation | $ | $ 287,774 | $ 29,015 | $ 1,439,194 | $ 321,228 | |
Option Activity, Number of shares | |||||
Balance, beginning of period | 959,188 | ||||
Granted | 869,253 | ||||
Balance, end of period | 1,828,441 | 1,828,441 | |||
Vested or expected to vest | 1,828,441 | 1,828,441 | |||
Exercisable | 657,099 | 657,099 | |||
Option Activity, Weighted-average exercise price | |||||
Beginning of period | $ / shares | $ 7.68 | ||||
Granted | $ / shares | 3.48 | ||||
End of period | $ / shares | $ 5.68 | 5.68 | |||
Vested or expected to vest | $ / shares | 5.68 | 5.68 | |||
Exercisable | $ / shares | $ 8.19 | $ 8.19 | |||
Option Activity, Fair value of options granted | |||||
Granted | $ | $ 2,124,922 | $ 2,124,922 | |||
Option Activity, Weighted-average remaining contractual term (in years) | |||||
Balance | 8 years 6 months 15 days | ||||
Vested or expected to vest | 8 years 6 months 15 days | ||||
Exercisable | 7 years 1 month 6 days | ||||
Research and development expense | |||||
Total stock-based compensation | $ | 43,861 | 13,986 | $ 95,013 | 57,353 | |
General and administrative | |||||
Total stock-based compensation | $ | $ 243,913 | $ 15,029 | 1,344,181 | $ 263,875 | |
General and administrative | Chief Executive Officer | |||||
Total stock-based compensation | $ | $ 781,266 | ||||
2011 stock incentive plan | |||||
Number of grants to be made under Plan | item | 0 | ||||
2015 Plan | |||||
Number of grants to be made under Plan | item | 0 | ||||
Common stock remaining for future issuance (in shares) | 464,476 | ||||
2016 Plan | |||||
Increase in number of shares reserved for issuance | 600,000 | ||||
Common stock remaining for future issuance (in shares) | 691,987 | 691,987 | |||
Annual share reserve increase (as a percent) | 4.00% |
Stock Based Compensation - Empl
Stock Based Compensation - Employee Stock Purchase Plan (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Jun. 30, 2016 | Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | May 18, 2016 | |
Employee Stock Purchase Plan | ||||||
Allocated Share-based Compensation Expense | $ 287,774 | $ 29,015 | $ 1,439,194 | $ 321,228 | ||
ESPP | ||||||
Employee Stock Purchase Plan | ||||||
Percentage of fair market value on the lower of first day or last day of the offering period at which employees may purchase stock under the ESPP | 85.00% | |||||
Maximum portion of earnings that employee may contribute to ESPP | 15.00% | |||||
Maximum annual amount of fair market value of the Company's common stock that a participant may accrue the rights to purchase | $ 25,000 | |||||
Common Stock, Capital Shares Reserved for Future Issuance | 500,000 | 500,000 | 500,000 | |||
Maximum increase in shares that may automatically increase at the first of the year as a percentage of the outstanding capital stock at the end of the preceding calendar year | 1.00% | |||||
Maximum automatic increase in the number of shares authorized for issuance | 500,000 | |||||
Allocated Share-based Compensation Expense | $ 36,690 | $ 43,213 |
Commitments And Contingencies36
Commitments And Contingencies (Details) - USD ($) | 6 Months Ended | 9 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | Sep. 30, 2016 | |
Period Of Abatement | 3 months | ||
Rent expense | $ 106,000 | $ 106,000 | |
Number of months left in the fiscal year | 3 years | ||
Future lease obligation: | |||
2,016 | $ 38,471 | ||
2,017 | 154,845 | ||
2,018 | 158,716 | ||
Total | 352,032 | ||
Research and Development Arrangement | |||
Obligation for future services | $ 1,700,000 |